These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24718698)

  • 1. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
    Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
    PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
    Javadi M; Richmond TD; Huang K; Barber DL
    J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The targeting of human and mouse B lymphocytes by dasatinib.
    Oksvold MP; Duyvestyn JM; Dagger SA; Taylor SJ; Forfang L; Myklebust JH; Smeland EB; Langdon WY
    Exp Hematol; 2015 May; 43(5):352-363.e4. PubMed ID: 25641047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
    Rathinam C; Thien CB; Flavell RA; Langdon WY
    Cancer Cell; 2010 Oct; 18(4):341-52. PubMed ID: 20951944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cbl-b is a negative regulator of inflammatory cytokines produced by IgE-activated mast cells.
    Gustin SE; Thien CB; Langdon WY
    J Immunol; 2006 Nov; 177(9):5980-9. PubMed ID: 17056522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
    Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
    Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
    An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
    Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.
    Nadeau SA; An W; Mohapatra BC; Mushtaq I; Bielecki TA; Luan H; Zutshi N; Ahmad G; Storck MD; Sanada M; Ogawa S; Band V; Band H
    J Biol Chem; 2017 Mar; 292(9):3666-3682. PubMed ID: 28082680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
    Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
    Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
    Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of function Cbl-c mutations in solid tumors.
    Daniels SR; Liyasova M; Kales SC; Nau MM; Ryan PE; Green JE; Lipkowitz S
    PLoS One; 2019; 14(7):e0219143. PubMed ID: 31260484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells.
    Oksvold MP; Dagger SA; Thien CB; Langdon WY
    Mol Immunol; 2008 Feb; 45(4):925-36. PubMed ID: 17868870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
    William BM; An W; Feng D; Nadeau S; Mohapatra BC; Storck MA; Band V; Band H
    Hematology; 2016 May; 21(4):218-24. PubMed ID: 26177294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
    Naramura M; Nandwani N; Gu H; Band V; Band H
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
    Sattler M; Pride YB; Quinnan LR; Verma S; Malouf NA; Husson H; Salgia R; Lipkowitz S; Griffin JD
    Oncogene; 2002 Feb; 21(9):1423-33. PubMed ID: 11857085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
    Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
    Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.